J&J Says Europe Clears New Diabetes Treatment
Johnson & Johnson said Friday that European Union regulators approved a pill that combines its diabetes drug Invokana with metformin, an older treatment for the disease.
Janssen-Cilag International will market the drug under the name Vokanamet. It is intended to treat type 2 diabetes, in which the body does not use insulin efficiently.
The U.S. Food and Drug Administration approved Invokana in March 2013. European Union authorities followed suit in November.
Shares of Johnson & Johnson lost 19 cents to $99.77 in midday trading.